Latest Breaking News On - Cancer imaging program - Page 1 : comparemela.com

Durvalumab Plus TACE and Bevacizumab Significantly Improves PFS in Select HCC

Durvalumab plus concurrent transarterial chemoembolization followed by durvalumab with bevacizumab resulted in a significant improvement in PFS over TACE alone in patients with hepatocellular carcinoma who are eligible for embolization, meeting the primary end point of the phase 3 EMERALD-1 trial.

Italy generalRiccardo lencioniSusan galbraithDurvalumab imfinziInternational liver cancer association virtual conferenceCancer imaging programInterventional radiologyPisa university hospitalLiver cancer association virtual conferenceDurvalumab plus concurrent transarterial chemoembolization followed by with bevacizumabTace alone in patients with hepatocellular carcinomaEligible for embolizationPrimary end point of the phase 3 emerald 1 trial

Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial

Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial
nationaltribune.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nationaltribune.com.au Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesSusan galbraithAstrazeneca imfinziDaiichi sankyoRiccardo lencioniCancer imaging programMerck co incBiosciences incInterventional radiologyPisa university hospitalExecutive vice presidentNorth americaSouth americaRare diseases

Imfinzi and Bevacizumab Hit Endpoint in Liver Cancer Trial

Imfinzi and Bevacizumab Hit Endpoint in Liver Cancer Trial
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesSusan galbraithAstrazeneca imfinziRiccardo lencioniDaiichi sankyoCancer imaging programBiosciences incMerck co incInterventional radiologyPisa university hospitalExecutive vice presidentNorth americaSouth americaRare diseases

IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial

IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesSouth koreaTransarterial chemoembolizationChelsea fordSusan galbraithBrendan mcevoyRiccardo lencioniDaiichi sankyoBiosciences incMerck co incWorld health organisationCancer imaging programInterventional radiologyPisa university hospitalExecutive vice president

Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial | Antibodies

Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial

City ofUnited kingdomSouth koreaUnited statesSusan galbraithAstrazeneca imfinziTransarterial chemoembolizationRiccardo lencioniDaiichi sankyoWorld health organisationCancer imaging programBiosciences incMerck co incUnited kingdomi novemberInterventional radiologyPisa university hospital